Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
Dec 1, 2022
13:54
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program.
Also, FDA approves the 1st fecal transplant product.
OncoPharm